Focus Partners Wealth Acquires 3,891 Shares of Edwards Lifesciences Corporation $EW

Key Points

• Focus Partners Wealth increased its stake in Edwards Lifesciences by 6.1% in Q1, owning 67,271 shares worth $4.87 million.
• Analysts have updated their price targets for Edwards Lifesciences, with Mizuho raising the target from $87.00 to $95.00, designating it as "outperform."
• Insider selling occurred recently, with VP Daniel J. Lippis selling 4,114 shares for approximately $327,000, resulting in a 15.75% decrease in ownership.

Focus Partners Wealth increased its stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 6.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 67,271 shares of the medical research company's stock after buying an additional 3,891 shares during the quarter. Focus Partners Wealth's holdings in Edwards Lifesciences were worth $4,876,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in EW. Quantbot Technologies LP acquired a new stake in shares of Edwards Lifesciences in the 1st quarter valued at approximately $26,000. Vega Investment Solutions acquired a new stake in shares of Edwards Lifesciences in the 4th quarter valued at approximately $27,000. SouthState Corp acquired a new stake in shares of Edwards Lifesciences in the 1st quarter valued at approximately $27,000. Global X Japan Co. Ltd. boosted its holdings in shares of Edwards Lifesciences by 116.1% in the 1st quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock valued at $29,000 after buying an additional 216 shares during the last quarter. Finally, Tradewinds Capital Management LLC boosted its holdings in shares of Edwards Lifesciences by 102.5% in the 1st quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock valued at $29,000 after buying an additional 205 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.

Insiders Place Their Bets

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the transaction, the insider owned 206,900 shares in the company, valued at $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the transaction, the vice president owned 22,002 shares in the company, valued at approximately $1,748,278.92. This represents a 15.75% decrease in their position. The disclosure for this sale can be found here. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Price Performance

Shares of NYSE EW traded down $0.16 during mid-day trading on Friday, reaching $74.39. The company had a trading volume of 8,177,895 shares, compared to its average volume of 3,799,900. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. Edwards Lifesciences Corporation has a one year low of $64.00 and a one year high of $83.00. The firm has a market cap of $43.67 billion, a price-to-earnings ratio of 10.70, a PEG ratio of 3.60 and a beta of 1.07. The business's 50-day simple moving average is $78.69 and its 200 day simple moving average is $75.51.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company had revenue of $1.53 billion for the quarter, compared to analysts' expectations of $1.49 billion. During the same quarter last year, the business earned $0.70 earnings per share. Edwards Lifesciences's revenue was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, research analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. The Goldman Sachs Group reissued a "buy" rating on shares of Edwards Lifesciences in a report on Friday, July 25th. Deutsche Bank Aktiengesellschaft raised their price target on Edwards Lifesciences from $85.00 to $94.00 and gave the company a "buy" rating in a report on Friday, July 25th. Argus raised Edwards Lifesciences to a "strong-buy" rating in a report on Thursday, July 10th. Wall Street Zen downgraded Edwards Lifesciences from a "strong-buy" rating to a "buy" rating in a report on Saturday, September 13th. Finally, Barclays raised their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the company an "overweight" rating in a report on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $87.17.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.